Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma

NCT00838591 is registered in ClinicalTrials.gov with MediciNova as lead sponsor.

NCT NCT00838591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00838591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma
Lead sponsor
MediciNova
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
March 31, 2012
Enrollment
176 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

asthma